Cato’s quarterly and year-end earnings report released Thursday morning was decidedly unimpressive, triggering our stop price so we are closing out this position. Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Analyst Articles
This is a list of portfolio changes found in the March 16, 2017 issue of Breakthrough Tech Profits. Read More
- March 16, 2017
-
Download Issue
Last summer I recommended buying LEAPS, or long-term call options, on Broadcom (NSDQ: AVGO) and Lam Research (NSDQ: LRCX). At the time, both stocks appeared undervalued, according to my IDEAL stock-rating system, and since then each has appreciated roughly 40%, confirming my analysis. I still like both companies, but… Read More
- March 16, 2017
-
Download Issue
It’s time to capitalize on Trump Disruption, and we know just how to do it. Read More
As a result of last week’s dip, our RPM noticed that STM is trading slightly below its 52-week high of $15.73 achieved on March 1, and appears close to breaking out above that level given its higher closing prices over the past three days. Read More
Doubts creep in over how much of his agenda the president can accomplish. Read More
Although this week’s quarterly earnings report for JONE came in a little better than expected, that wasn’t good enough to keep it from closing below its stop price so I have to close out this position. Read More
Doubts creep in over how much of his agenda the president can accomplish. Read More
With interest in so-called “Trump stocks” beginning to wane now that those campaign promises must fit into a budget, investors are beginning to look for value and a stock like HBI, trading at less than 10x forward earnings with an IDEAL score of 8, may be just what they are looking for. Read More
Buy the Synergy Pharmaceuticals (NSDQ: SGYP) April 21, 2017 $5.50 call option up to $0.60. Read More